Sanofi
- Country
- ๐ซ๐ทFrance
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1210
- Registration Number
- NCT04751487
- Locations
- ๐บ๐ธ
Temple University Hospital Site Number : 8400062, Philadelphia, Pennsylvania, United States
๐บ๐ธRemington-Davis Inc Site Number : 8400004, Columbus, Ohio, United States
๐บ๐ธCare Access Site Number : 8400276, Boston, Massachusetts, United States
Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 456
- Registration Number
- NCT04717375
- Locations
- ๐บ๐ธ
Mayo Clinic Hospital- Site Number : 8400003, Phoenix, Arizona, United States
๐บ๐ธCity of Hope Comprehensive Cancer Center- Site Number : 8400002, Duarte, California, United States
๐บ๐ธSmilow Cancer Center at Yale-New Haven- Site Number : 8400001, New Haven, Connecticut, United States
Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 41
- Registration Number
- NCT04718870
- Locations
- ๐ฌ๐ง
Investigational Site Number :8260001, Sheffield, United Kingdom
๐บ๐ธInvestigational Site Number :8400002, Los Angeles, California, United States
๐บ๐ธInvestigational Site Number :8400001, Denver, Colorado, United States
Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 24
- Registration Number
- NCT04705051
- Locations
- ๐ณ๐ฑ
Investigational Site Number :5280002, Nijmegen, Netherlands
๐ฏ๐ตInvestigational Site Number :3920007, Osaka-shi, Osaka, Japan
๐ฏ๐ตInvestigational Site Number :3920002, Bunkyo-ku, Tokyo, Japan
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2021-01-08
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 960
- Registration Number
- NCT04701983
- Locations
- ๐บ๐ธ
MACRO Trials Site Number : 8400030, Los Angeles, California, United States
๐บ๐ธCovenant Pulmonary Critical Care Site Number : 8400183, Atlanta, Georgia, United States
๐บ๐ธClinical Research of Central PA Site Number : 8400023, DuBois, Pennsylvania, United States
Dupilumab in Allergic Fungal Rhinosinusitis (AFRS) (LIBERTY-AFRS-AI)
- Conditions
- Interventions
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 62
- Registration Number
- NCT04684524
- Locations
- ๐ธ๐ฆ
Investigational Site Number : 6820001, Riyadh, Saudi Arabia
๐น๐ทInvestigational Site Number : 7920007, Istanbul, Turkey
๐ฆ๐ทInvestigational Site Number : 0320004, Mendoza, Argentina
Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)
- Conditions
- Interventions
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 82
- Registration Number
- NCT04681729
- Locations
- ๐ฏ๐ต
Investigational Site Number :3920008, Kamimashiki Gun, Kumamoto, Japan
๐บ๐ธAllergy and Asthma Medical Group and Research Center-Site Number:8400001, San Diego, California, United States
๐บ๐ธJohns Hopkins University (Asthma and Allergy Center)-Site Number:8400005, Baltimore, Maryland, United States
Dupilumab in Japanese Patients With Atopic Dermatitis
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 62
- Registration Number
- NCT04678882
- Locations
- ๐ฏ๐ต
Investigational Site Number : 3920011, Nagoya-shi, Aichi, Japan
๐ฏ๐ตInvestigational Site Number : 3920014, Toyoake-shi, Aichi, Japan
๐ฏ๐ตInvestigational Site Number : 3920015, Fukutsu-shi, Fukuoka, Japan
Dupilumab in CRSsNP
- Conditions
- Interventions
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 71
- Registration Number
- NCT04678856
- Locations
- ๐บ๐ฆ
Investigational Site Number : 8040008, Kyiv, Ukraine
๐บ๐ธPharmaceutical Research & Consulting, Inc. Site Number : 8400006, Dallas, Texas, United States
๐บ๐ธAlamo ENT Associates Site Number : 8400021, San Antonio, Texas, United States
A Study to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia Not Adequately Controlled on Statin Therapy
- Conditions
- Interventions
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 305
- Registration Number
- NCT04669041
- Locations
- ๐จ๐ณ
Investigational Site Number :1560006, Hohhot, China
๐จ๐ณInvestigational Site Number :1560045, Changchun, China
๐จ๐ณInvestigational Site Number :1560067, Changchun, China